Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD70 CAR-T cells (Weijia Fang)
- Development stage
- Unknown
- Lead developer
- Chongqing Precision Biotech Co., Ltd
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intraperitoneal
01
Overview
CD70 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD70 (also known as TNFSF7), a surface protein frequently overexpressed in various malignancies including renal cell carcinoma, ovarian cancer, and cervical cancer, while maintaining limited expression in healthy tissues. Developed as an investigator-initiated therapy by Dr. Weijia Fang at Zhejiang University, these engineered T cells are programmed to recognize and eliminate CD70-positive tumor cells. The therapy is currently undergoing Phase I clinical evaluation to assess safety, tolerability, and preliminary efficacy in patients with advanced or metastatic solid tumors, utilizing both intravenous and intraperitoneal administration routes.
- Other names
- CD70-targeted CAR-T cellsCD-70-targeted CAR-T cellsCD 70-targeted CAR-T cellsCD70-targeting CAR-T therapyCD-70-targeting CAR-T therapyCD 70-targeting CAR-T therapy
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on CD70 CAR-T cells (Weijia Fang).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD70 CAR-T cells (Weijia Fang).